This brand name is authorized in United States.
The drug RYTELO contains one active pharmaceutical ingredient (API):
1
|
UNII
F60NE4XB53 - IMETELSTAT
|
|
Imetelstat is an oligonucleotide telomerase inhibitor that binds to the template region of the RNA component of human telomerase (hTR), which prevents telomere binding. Telomerase activity and human telomerase reverse transcriptase (hTERT) RNA expression are known to be significantly increased in MDS and malignant stem and progenitor cells. Imetelstat treatment leads to reduction of telomere length, inhibition of malignant stem and progenitor cell proliferation and induction of apoptotic cell death leading to reduction of malignant clones. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| RYTELO Powder for concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| RYTELO Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| L01XX80 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| US | FDA, National Drug Code | 82959-111, 82959-112 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.